?
Parkinson’s disease: network analysis of publications’ activity
Polski Przegląd Neurologiczny. 2018. P. 148-149.
Language:
English
Keywords: Parkinson’s disease
Publication based on the results of:
Hyder R., Jensen M., Højlund A. et al., NeuroImage: Clinical 2021 No. 102718
Parkinson’s disease (PD) is a neurodegenerative disorder, well-known for its motor symptoms; however, it also adversely affects cognitive functions, including language, a highly important human ability. PD pathology is associated, even in the early stage of the disease, with alterations in the functional connectivity within corticosubcortical circuitry of the basal ganglia as well as within ...
Added: January 21, 2022
Blokhin V., Lavrova A., Surkov S. et al., International Journal of Molecular Sciences 2022 Vol. 23 No. 7 Article 3678
This is the first study aiming to develop a method for the long-term visualization of living nigrostriatal dopaminergic neurons using 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine-BODIPY (GBR-BP), the original fluorescent substance, which is a derivative of GBR-12909, a dopamine uptake inhibitor. This method is based on the authors’ hypothesis about the possibility of specifically internalizing into dopaminergic neurons substances with ...
Added: March 4, 2024
Alieva A. K., Zyrin V. S., Rudenok M. M. et al., Molecular Neurobiology 2018 Vol. 55 No. 9 P. 7229-7241
Parkinson's disease (PD) is characterized by degeneration of dopaminergic neurons. A whole-transcriptome analysis of the substantia nigra and striatum of an MPTP-induced mouse models of the earliest stages of PD was performed. Functional clustering of differentially represented transcripts revealed processes associated with the functioning of synapses, dendrites, axons, and myelination of neuronal projections. All of ...
Added: September 9, 2022
Ugrumov M., Acta Naturae 2019 Vol. 11 No. 4 P. 99-103
An important approach to an early diagnosis of Parkinson’s disease (PD) is screening for peripheral biomarkers in patients at the early clinical stage. In this study, we evaluated catecholamine concentration changes in the tear fluid of untreated PD patients as biomarkers. Norepinephrine and dopamine concentrations in the tear fluid of patients were found to increase ...
Added: December 6, 2020
Hohlefeld F. U., Huchzermeyer C., Huebl J. et al., Neuroscience 2013 No. 250 P. 320-332
In Parkinson's disease (PD) levodopa-associated changes in the power and long-range temporal correlations of beta oscillations have been demonstrated, yet the presence and modulation of genuine connectivity in local field potentials (LFP) recorded from the subthalamic nucleus (STN) remains an open question. The present study investigated LFP recorded bilaterally from the STN at wakeful rest ...
Added: October 23, 2014
Kim A., Nigmatullina R., Zalyalova Z. et al., Molecular Neurobiology 2019 Vol. 56 No. 5 P. 3437-3450
Numerous attempts to develop an early diagnosis of Parkinson’s disease (PD) by searching biomarkers in biological fluids were unsuccessful. The drawback of this methodology is searching markers in patients at the clinical stage without guarantee that they are also characteristic of either preclinical stage or prodromal stage (preclinical–prodromal stage). We attempted to upgrade this methodology ...
Added: January 12, 2022
Katunina E., Blokhin V., Nodel M. et al., International Journal of Molecular Sciences 2023 Vol. 24 No. 3 Article 1842
Parkinson’s disease (PD) is diagnosed many years after its onset, under a significant degradation of the nigrostriatal dopaminergic system, responsible for the regulation of motor function. This explains the low effectiveness of the treatment of patients. Therefore, one of the highest priorities in neurology is the development of the early (preclinical) diagnosis of PD. The ...
Added: March 4, 2024
Самушия М. А., Ragimova A., Кремлевская медицина. Клинический вестник 2019 № 1 С. 58-68
The review presents the data on the effects of the COMT, MAO-A, MAO-B, DAT, DRD2, VMAT2, TPH2 and SNCA genes on Parkinson's disease, the effectiveness of therapy and theiraffinity to a number of mental disorders. A systematic review was conducted with 77 articles and monographs devoted to the problems of genetics, neurology and psychiatry, published ...
Added: December 11, 2020
Ragimova A., Самушия М. А., Иволгин А. Ф. et al., Кремлевская медицина. Клинический вестник 2019 № 4 С. 45-56
Neuropsychiatric symptoms of Parkinson's disease are some of the factors determining the patient's quality of life, but often remain underestimated by clinicians, especially in the prodromal stage, when affective symptoms can be assessed without regard to the neurological disease. Objective: to study the clinical characteristics of affective disorders and their comorbid pathological characteristics, manifesting in ...
Added: December 11, 2020
Kolacheva A., Bannikova A., Pavlova E. et al., International Journal of Molecular Sciences 2023 Vol. 24 No. 1 Article 683
The fight against neurodegenerative diseases, including Parkinson’s disease (PD), is among the global challenges of the 21st century. The low efficiency of therapy is due to the late diagnosis and treatment of PD, which take place when there is already significant degradation of the nigrostriatal dopaminergic system, a key link in the regulation of motor ...
Added: March 1, 2024
Kolacheva A., Pavlova E., Bannikova A. et al., International Journal of Molecular Sciences 2023 Vol. 24 No. 3 Article 3027
Given the limited access to clinical material for studying the pathogenesis of Parkinson's disease (PD), these studies should be carried out on experimental models. We have recently developed a subchronic model of the progressive development of PD with a gradual transition from the preclinical (asymptomatic) stage to the clinical (symptomatic) one. The aim of this ...
Added: March 1, 2024
Safandeev V. V., Ugrumov M., Neuroscience and Behavioral Physiology 2020 Vol. 50 No. 4 P. 451-458
A characteristic feature of Parkinson’s disease (PD) is the fact that it is diagnosed only at the late, “clinical”
stage due to onset of motor symptoms on the background of almost complete degradation of the dopaminergic
nigrostriatal system. This explains the low effi cacy of existing replacement therapy (dopamine agonists)
and produces the need to develop early (preclinical) ...
Added: January 12, 2022
Blokhin V. E., M. V. Ugryumov, Neurochemical Journal 2021 Vol. 15 No. 1 P. 18-23
One of the priorities of neuroscience is the fight against socially relevant neurodegenerative diseases, including Parkinson’s disease (PD). Given the limited possibilities of studying the pathogenesis of this disease, the creation and detailed study of appropriate experimental models is of great importance. Therefore, the purpose of this work was to continue the long-term study of ...
Added: March 4, 2024
Khakimova G., Kozina E., Kucheryanu V. et al., Molecular Neurobiology 2016 Vol. 54 No. 5 P. 3618-3632
A crucial event in the pathogenesis of Parkinson’s disease is the death of dopaminergic neurons of the nigrostriatal system, which are responsible for the regulation of motor function. Motor symptoms first appear in patients 20–30 years after the onset of the neurodegeneration, when there has been a loss of an essential number of neurons and ...
Added: July 1, 2016
Denisova I., Chubarova T., Bogatova I. et al., Population and Economics 2020 Vol. 4 No. 3 P. 111-127
Added: September 15, 2023
Ahuja M., Ammal Kaidery N., Attucks O. et al., Proceedings of the National Academy of Sciences of the United States of America 2021 Vol. 118 No. 45 Article e2111643118
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by the loss of nigrostriatal dopaminergic neurons. Mounting evidence suggests that Nrf2 is a promising target for neuroprotective interventions in PD. However, electrophilic chemical properties of the canonical Nrf2-based drugs cause irreversible alkylation of cysteine residues on cellular proteins resulting in side effects. Bach1 is ...
Added: January 17, 2022
Mingazov E., Khakimova G., Kozina E. et al., Molecular Neurobiology 2017 P. 1-16
Parkinson’s disease (PD) is characterized by the appearance of motor symptoms many years after the onset of neurodegeneration, which explains low efficiency of therapy. Therefore, one of the priorities in neurology is to develop an early diagnosis and preventive treatment of PD, based on knowledge of molecular mechanisms of neurodegeneration and neuroplasticity in the nigrostriatal ...
Added: June 7, 2017
Ugrumov M., Molecular Neurobiology 2018 P. 1-16
Parkinson’s disease (PD) is characterized by the appearance of motor symptoms many years after the onset of neurodegeneration, which explains low efficiency of therapy. Therefore, one of the priorities in neurology is to develop an early diagnosis and preventive treatment of PD, based on knowledge of molecular mechanisms of neurodegeneration and neuroplasticity in the nigrostriatal ...
Added: December 6, 2020
Bogdanov V., Kim A., Nodel M. et al., International Journal of Molecular Sciences 2021 Vol. 22 No. 9 Article 4736
Development of differential and early (preclinical) diagnostics of Parkinson’s disease (PD) is among the priorities in neuroscience. We searched for changes in the level of catecholamines and α-2-macroglobulin activity in the tear fluid (TF) in PD patients at an early clinical stage. It was shown that TF in patients is characterized by an increased level ...
Added: March 4, 2024
Beliakov S., Blokhin V., Surkov S. et al., International Journal of Molecular Sciences 2023 Vol. 24 No. 1 Article 733
The low effectiveness of symptomatic pharmacotherapy for Parkinson’s disease (PD), which compensates for dopamine (DA) deficiency under degeneration of nigrostriatal dopaminergic (DAergic) neurons, could apparently be improved with neuroprotective therapy, which slows down neurodegeneration and PD progression. For this, it is necessary to have a DAergic cell line for the development of a PD model ...
Added: March 1, 2024
Fuad Aleskerov, Khutorskaya O., Viacheslav Yakuba et al., Computational Management Science 2024 Vol. 21 Article 13
Parkinson’s disease is the second most common neurodegenerative disorder in the world. Thousands of scientific works are published every year. We have analyzed more than 3 thousand organizations, who have published works on various aspects of parkinson’s disease in the period from 2015 to 2021. We have evaluated 4 classical centrality indices (In-degree, Eigenvector, Pagerank ...
Added: March 6, 2024
Kim A., Pavlova E., Kolacheva A. et al., Biomedicine and Pharmacotherapy 2022 Vol. 150 Article 112944
The fight against neurodegenerative diseases, including Parkinson’s disease (PD), is a global challenge of this century. The effectiveness of current PD therapy is limited, since it is diagnosed many years after the onset, following the death of most nigrostriatal dopaminergic neurons regulating motor function. PD treatment could be greatly improved if it was started at ...
Added: March 4, 2024